Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026. Carvolix SA was founded in 2011 and is headquartered in Aix-en-Provence, France.
Metrics to compare | CVXC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCVXCPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.4x | −3.1x | −0.5x | |
PEG Ratio | −0.34 | −0.11 | 0.00 | |
Price/Book | 7.3x | 1.9x | 2.6x | |
Price / LTM Sales | 29.1x | 2.3x | 3.3x | |
Upside (Analyst Target) | −10.3% | 46.7% | 45.7% | |
Fair Value Upside | Unlock | 12.6% | 6.5% | Unlock |